. 2022 Jun 13;57(10):629–638. doi: 10.1097/RLI.0000000000000889

TABLE 1.

Physicochemical Properties of GBCAs (Market Products and Development Candidates)

	Net Charge	GBCA Generic Name	Chelate Backbone	No. Inner Sphere Water Molecules	Gd Concentration of Formulation, mol Gd/L	r1-Relaxivity in Human Plasma at 37°C, mM⁻¹ s⁻¹		Log P (1-Butanol/Buffer)	Osmolality at 37°C, mosmol/kg H₂O	Viscosity at 37°C, mPa·s
	Net Charge	GBCA Generic Name	Chelate Backbone	No. Inner Sphere Water Molecules	Gd Concentration of Formulation, mol Gd/L	1.5 T	3.0 T	Log P (1-Butanol/Buffer)	Osmolality at 37°C, mosmol/kg H₂O	Viscosity at 37°C, mPa·s
In clinical development	Nonionic	Gadoquatrane (BAY 1747846)	Gd-GlyMe-DOTA (tetramer)	q = 1	0.3 (0.075 per molecule)	11.8 ± 0.3* (47.2 ± 1.0 per molecule)	10.5 ± 0.3 (41.9 ± 0.6 per molecule)	−4.32	294 (iso-osmolar to blood)	1.22
In clinical development	Nonionic	Gadopiclenol	Gd-PCTA	q = 2†	0.5	12.8‡	11.6‡	−4.2†	843†	7.6∥
Market products	Nonionic	Gadobutrol	Gd-BT-DO3A	q = 1	1.0	4.8 ± 0.1§	5.0 ± 0.6§	−2.22	1603∥	5.0∥
	Nonionic	Gadoteridol	Gd-HP-DO3A	q = 1	0.5	3.8 ± 0.1§	3.3 ± 0.1§	−1.98∥	630∥	1.3∥
	Ionic	Gadoterate meglumine	Gd-DOTA	q = 1	0.5	3.3 ± 0.1§	3.0 ± 0.1§	−2.87∥	1350∥	2.0∥

*60 MHz (1.41 T) values for BAY 1747846, mean ± SD (n = 6 synthesized batches).

†Robic et al,²¹P value in octanol/PBS.

‡Fries et al,²² reconstituted lyophilized human plasma.

§Szomolanyi et al.²³

∥Port et al.²⁴

GBCA, gadolinium-based contrast agent.